期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
Programmed cell death 1 inhibitor sintilimab plus concurrent chemoradiotherapy for locally advanced pancreatic adenocarcinoma
1
作者 Shi-Qiong Zhou Peng Wan +3 位作者 Sen Zhang Yuan Ren Hong-Tao Li qing-hua ke 《World Journal of Clinical Oncology》 2024年第7期859-866,共8页
BACKGROUND Pancreatic adenocarcinoma,a malignancy that arises in the cells of the pancreas,is a devastating disease with unclear etiology and often poor prognosis.Locally advanced pancreatic cancer,a stage where the t... BACKGROUND Pancreatic adenocarcinoma,a malignancy that arises in the cells of the pancreas,is a devastating disease with unclear etiology and often poor prognosis.Locally advanced pancreatic cancer,a stage where the tumor has grown significantly but has not yet spread to distant organs,presents unique challenges in treatment.This article aims to discuss the current strategies,challenges,and future directions in the management of locally advanced pancreatic adenocarcinoma(LAPC).AIM To investigate the feasibility and efficacy of programmed cell death 1(PD-1)inhibitor sintilimab plus concurrent chemoradiotherapy for LAPC.METHODS Eligible patients had LAPC,an Eastern cooperative oncology group performance status of 0 or 1,adequate organ and marrow functions,and no prior anticancer therapy.In the observation group,participants received intravenous sintilimab 200 mg once every 3 wk,and received concurrent chemoradiotherapy(concurrent conventional fractionated radiotherapy with doses planning target volume 50.4 Gy and gross tumor volume 60 Gy in 28 fractions and oral S-140 mg/m2 twice daily on days 1-14 of a 21-d cycle and intravenous gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-d cycle for eight cycles until disease progression,death,or unacceptable toxicity).In the control group,participants only received concurrent chemoradiotherapy.From April 2020 to November 2021,64 participants were finally enrolled with 34 in the observation group and 30 in the control group.RESULTS Thirty-four patients completed the scheduled course of chemoradiotherapy,while 32(94.1%)received sintilimab plus concurrent chemoradiotherapy with 2 patients discontinuing sintilimab in the observation group.Thirty patients completed the scheduled course of chemoradiotherapy in the control group.Based on the Response Evaluation Criteria in Solid Tumors guidelines,the analysis of the observation group revealed that a partial response was observed in 11 patients(32.4%),stable disease was evident in 19 patients(55.9%),and 4 patients(11.8%)experienced progressive disease;a partial response was observed in 6(20.0%)patients,stable disease in 18(60%),and progressive disease in 6(20%)in the control group.The major toxic effects were leukopenia and nausea.The incidence of severe adverse events(AEs)(grade 3 or 4)was 26.5%(9/34)in the observation group and 23.3%(7/30)in the control group.There were no treatment-related deaths.The observation group demonstrated a significantly longer median overall survival(22.1 mo compared to 15.8 mo)(P<0.05)and progression-free survival(12.2 mo vs 10.1 mo)(P<0.05)in comparison to the control group.The occurrence of severe AEs did not exhibit a statistically significant difference between the observation group and the control group(P>0.05).CONCLUSION Sintilimab plus concurrent chemoradiotherapy was effective and safe for LAPC patients,and warrants further investigation. 展开更多
关键词 IMMUNOTHERAPY Concurrent chemoradiotherapy Locally advanced pancreatic adenocarcinoma Programmed cell death 1 Sintilimab
下载PDF
S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer 被引量:8
2
作者 qing-hua ke Shi-Qiong Zhou +4 位作者 Ji-Yuan Yang Wei Du Gai Liang Yong Lei Fei Luo 《World Journal of Gastroenterology》 SCIE CAS 2014年第38期13987-13992,共6页
AIM: To investigate the feasibility and efficacy of the combination of S-1 with gemcitabine followed by oral S-1 with concurrent radiotherapy (intensity modulated radiotherapy, IMRT) and maintenance therapy with S-1 f... AIM: To investigate the feasibility and efficacy of the combination of S-1 with gemcitabine followed by oral S-1 with concurrent radiotherapy (intensity modulated radiotherapy, IMRT) and maintenance therapy with S-1 for locally advanced pancreatic cancer. 展开更多
关键词 CHEMORADIOTHERAPY RADIOSENSITIZER S-1 Pancreatic cancer CA19-9
下载PDF
Helicity-dependent time delays in multiphoton ionization by two-color circularly polarized laser fields
3
作者 qing-hua ke Yue-Ming Zhou +5 位作者 Yi-Jie Liao Jin-Tai Liang Yong Zhao Jia Tan Min Li Pei-Xiang Lu 《Frontiers of physics》 SCIE CSCD 2021年第5期3-9,共7页
By numerically solving the three-dimensional time-dependent Schrödinger equation,we have investigated multiphoton ionization of hydrogen atom in the two-color circularly polarized(TCCP)laser fields consisting of ... By numerically solving the three-dimensional time-dependent Schrödinger equation,we have investigated multiphoton ionization of hydrogen atom in the two-color circularly polarized(TCCP)laser fields consisting of a strong 400 nm and a much weaker 800 nm pulses.Due to the presence of perturbative 800 nm laser pulse,sideband peaks emerge between the above-threshold ionization rings in the photoelectron momentum distributions.Our numerical results show that the sideband peaks exhibit one-lobe structure in the co-rotating TCCP laser fields,while it displays the three-lobe structure in the counter-rotating TCCP laser fields.Moreover,the photoelectron yield of sidebands in the co-rotating TCCP fields is much higher than those of the counter-rotating TCCP fields.These phenomena could be well explained from the perspective of the photon-absorption channels via the selection rules.Interestingly,an obvious phase shift between the sidebands of different orders from the co-rotating and counter-rotating TCCP fields is observed.This shift indicates the helicity-dependent time delay in the one-photon continuum-continuum transition process. 展开更多
关键词 helicity-dependent time delay TCCP multiphoton ionization
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部